drugset
drugset / Trial / NCT06906198

Pharmacokinetics of VVN461 Ophthalmic Solution

NCT06906198 ↗

Phase 1 Completed 30 enrolled VivaVision Biotech, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single-center, double-masked, randomized, vehicle-controlled study conducted in China in adult healthy subjects

Timeline

Start
2023-03-01
Primary completion
2023-05-10
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject VVN461 Unknown 0.25 % Other
Subject VVN461 Unknown 0.5 % Other
Subject VVN461 Unknown 1 % Other

Indications

No indication recorded.